Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd
Expands Avadel’s pipeline with salt-free, artificial sweetener-free, once-at-bedtime oxybate for treatment of narcolepsy and idiopathic hypersomnia. XWPharma to receive $20 million upfront; potential for development, regulatory and sales milestone payments in addition to royalties on future net sales
Article Date
September 3, 2025
This article is featured on another website.
Go to article
March 6, 2026
Labiotech Beyond Biotech podcast with Sean A. MacDonald, CEO of Kainova Therapeutics – Reversing tumor immunosuppression with next-gen GPCR modulation
March 6, 2026
Labiotech Beyond Biotech podcast with Sean A. MacDonald, CEO of Kainova Therapeutics – Reversing tumor immunosuppression with next-gen GPCR modulation
April 28, 2026
Clinical Research Consulting vs. FSP in Biotech and Pharma: Knowing When an FSP Is the Right Fit
Clinical Research Consulting vs. FSP: Choosing the Right Model for Biotech and Pharma Companies Biotech…
April 28, 2026
Clinical Research Consulting vs. FSP in Biotech and Pharma: Knowing When an FSP Is the Right Fit
Clinical Research Consulting vs. FSP: Choosing the Right Model for Biotech and Pharma Companies Biotech…